TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7602364
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy directed at large-cell lymphomas
Study: 30870102
Drug: Single session
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single session of Behavioural Activation followed by 8 weeks of daily SMS messages (INT)
Study: 26275599
Drug: GentleWave System
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GentleWave System (GWS) treatment
Study: 22729012
Drug: Intravenous tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous tranexamic acid (1.5 g mixed in 100 cc of saline)
Study: 22729012
Drug: Intra-articular tranexamic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular tranexamic acid (1.5 g mixed in 100 cc of saline)
Study: 22729012
Drug: Placebo (normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (normal saline administered into the knee joint cavity and intravenously)
Study: 16005883
Drug: Atorvastatin and
Normalized name: atorvastatin and ezetimibe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin and Simvastatin
Study: 11725155
Drug: HRT 1
Normalized name: FEMHRT 1/5 TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRT 1 (1 mg of 17beta‐oestradiol per day continuously plus 0.025 mg gestodene on days 17‐28 of each 4‐week cycle)
Study: 11725155
Drug: HRT 2
Normalized name: EE/NETHDRONE (EQV-FEMHRT 2.5/0.5) TAB,28
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRT 2 (1 mg of 17beta‐oestradiol per day continuously plus gestodene in each third cycle only)
Study: 9165186
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg fluoride daily in the form of a tablet
Study: 3309479
Drug: Group I
Normalized name: Platelet group IIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group I (one-dose protocol): All protamine infused within 10 minutes after termination of cardiopulmonary bypass.
Study: 3309479
Drug: Group II
Normalized name: Platelet group IIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group II (two-dose protocol): 75% of the calculated protamine dose infused within 10 minutes after termination of bypass, remainder after transfusion of all blood in the heart-lung machine.
Study: 27228512
Drug: Dexmedetomidine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.5 µg/kg (DEX I group)
Study: 27228512
Drug: Dexmedetomidine 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.3 µg/kg (DEX II group)
Study: 27228512
Drug: Dexmedetomidine 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.2 µg/kg (DEX III group)
Study: 27228512
Drug: Meperidine 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine 0.4 mg/kg (meperidine group)
Study: 22353612
Drug: Antioxidant cocktail
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant cocktail (vitamin C, 1000 mg; vitamin E, 600 IU; α‐lipoic acid, 600 mg)
Study: 18953651
Drug: Chemoendocrine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoendocrine treatment
Study: 15842141
Drug: Aitongping capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aitongping capsule (ATP)
Study: 12851275
Drug: Promensil (82
Approvals — FDA: no, EMA: no, PMDA: no
Description: Promensil (82 mg of total isoflavones per day)
Study: 12851275
Drug: Rimostil (57
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rimostil (57 mg of total isoflavones per day)
Study: 1746418
Drug: Oral controlled-release
Normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral controlled-release mononitrate for 1 month
Study: 1746418
Drug: Oral captopril
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral captopril for 1 month
Study: 1746418
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium for 24 hours
Study: 1746418
Drug: Placebo for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for oral controlled-release mononitrate
Study: 1746418
Drug: Placebo for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for oral captopril
Study: 1746418
Drug: Open control
Normalized name: BOTTLE OPENER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open control (no infusion) for intravenous magnesium
Study: 6137945
Drug: Beta blockers
Normalized name: BETA BLOCKERS/RELATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta blockers (e.g., practolol, timolol, propranolol)
Study: 6137945
Drug: Propranolol (Beta‐Blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (Beta‐Blocker Heart Attack Trial)
Study: 30694523
Drug: Bevacizumab with
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab with neoadjuvant chemotherapy (NCT)
Study: 26497831
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplementation providing 1400 mg per day EPA+DHA
Study: 17465862
Drug: LT4/LT3 combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: LT4/LT3 combined therapy
Study: 11487166
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g of amoxicillin
Study: 11487166
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g of placebo control
Study: 3294124
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy with cimetidine 1 g daily and cisapride 40 mg daily
Study: 3294124
Drug: Single drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single drug therapy (cimetidine and placebo)
Study: 3294124
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy with cimetidine + cisapride
Study: 21765368
Drug: Atorvastatin 80
Normalized name: atorvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 80 mg once daily for 7 days with fimasartan 240 mg
Study: 21765368
Drug: Atorvastatin 80
Normalized name: atorvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 80 mg once daily for 7 days
Study: 19835119
Drug: Warming needling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warming needling treatment combined with cupping (needle inserted on sciatic nerve at Huantiao (GB 30))
Study: 19835119
Drug: Warming needling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warming needling treatment combined with cupping (needle not needled on sciatic nerve)
Study: 11563999
Drug: Ibuprofen 2400
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 2400 mg daily
Study: 9700954
Drug: Bombesin infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bombesin infusion (1 ng/kg x min) during hyperglycemia
Study: 7716349
Drug: Bamiphylline (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bamiphylline (600 mg b.d. for 15 days)
Study: 7716349
Drug: Placebo (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (600 mg b.d. for 15 days)
Study: 9701388
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (i.v.Ig) prophylaxis
Study: 8017316
Drug: Diltiazem CD
Normalized name: Diltiazem Hydrochloride 300 MG Oral Capsule, Extended Release, 24 HR [DILTIAZEM CD]
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diltiazem CD (DCD) 60 mg
Study: 8017316
Drug: Diltiazem CD
Normalized name: Diltiazem Hydrochloride 300 MG Oral Capsule, Extended Release, 24 HR [DILTIAZEM CD]
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diltiazem CD (DCD) 120 mg
Study: 8017316
Drug: Diltiazem CD
Normalized name: Diltiazem Hydrochloride 300 MG Oral Capsule, Extended Release, 24 HR [DILTIAZEM CD]
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diltiazem CD (DCD) 240 mg
Study: 8017316
Drug: Diltiazem CD
Normalized name: Diltiazem Hydrochloride 300 MG Oral Capsule, Extended Release, 24 HR [DILTIAZEM CD]
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diltiazem CD (DCD) 360 mg
Study: 8017316
Drug: Diltiazem CD
Normalized name: Diltiazem Hydrochloride 300 MG Oral Capsule, Extended Release, 24 HR [DILTIAZEM CD]
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diltiazem CD (DCD) 480 mg
Study: 2400071
Drug: Guedel oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guedel oral airway
Study: 71602
Drug: (−)‐deprenyl 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: (−)‐deprenyl 10 mg daily or on alternate days
Study: 71602
Drug: (−)‐deprenyl with
Approvals — FDA: no, EMA: no, PMDA: no
Description: (−)‐deprenyl with smaller total daily doses of levodopa and a peripheral decarboxylase inhibitor
Study: 30942013
Drug: Intradermal needling
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal needling after pterygium resection
Study: 23137103
Drug: Propofol (1%)
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol (1%) administered at a dose of 3 mg·kg(‐1) intravenously, maintained by propofol infusion (0.5%) at 12 mg·kg(‐1·) h(‐1) for the first 20 min and at 8 mg·kg(‐1·) h(‐1) thereafter
Study: 16373890
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of hypoglycemia with 15 g of oral glucose
Study: 12727976
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) 0.043 mg/kg x d
Study: 25742759
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg losartan
Study: 25742759
Drug: Increase in
Normalized name: Incruse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increase in SCr >0.3 mg/dl
Study: 25742759
Drug: Increase in
Normalized name: Incruse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increase in SCr >0.3 mg/dl before 4 months
Study: 20622687
Drug: Clevidipine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clevidipine (0.5 mg/mL in 20% lipid solution, initiated at 10 mg/h and titrated to effect)
Study: 8252157
Drug: Ceftazidime alone
Normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftazidime alone 3 g/day (Group C)
Study: 8252157
Drug: Ceftazidime 3
Normalized name: ceftazidime 30 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime 3 g/day plus amikacin 15 mg/kg/day (Group CA)
Study: 8252157
Drug: Ceftazidime 3
Normalized name: ceftazidime 30 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime 3 g/day plus vancomycin 1.5 g/day (Group CV)
Study: 15939243
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids (ICS) therapy for 2 months
Study: 8916749
Drug: Xylitol chewing
Normalized name: xylitol Chewing Gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xylitol chewing gum (8.4 g a day)
Study: 1927519
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) dose regimen of 15 IU/m2/week as daily s.c. injections
Study: 1927519
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) dose regimen of 30 IU/m2/week
Study: 6350994
Drug: Intravenous guanethidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous guanethidine block
Study: 30732624
Drug: Carer-administration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carer-administration of as-needed subcutaneous medication for breakthrough symptoms (pain, nausea, restlessness, noisy breathing) with manualised training package delivered by local nursing team.
Study: 7575714
Drug: Amitriptyline (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (25 mg/day)
Study: 20884622
Drug: Autologous tumor
Normalized name: DNP-Modified autologous tumor vaccine
DrugBank: DNP-Modified autologous tumor vaccine (DB17436)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous tumor lysate- and KLH-pulsed DC vaccine
Study: 25098116
Drug: Conventional prevention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional prevention (topical corticosteroids)
Study: 22989898
Drug: Intensive SBP
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive SBP reduction (to <=140mmHg) using intravenous nicardipine infusion for 24 hours post-randomization
Study: 18021872
Drug: Pioglitazone 30
Normalized name: pioglitazone 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone 30 mg daily for 4 weeks, followed by 45 mg daily for 12 weeks
Study: 16040446
Drug: High-dose xylitol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose xylitol (HX; 6.0 g xylitol)
Study: 16040446
Drug: Low-dose xylitol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose xylitol (LX; 2.0 g xylitol)
Study: 8009976
Drug: Interferon-beta (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-beta (2 x 10(6) I.U. daily) for ten days
Study: 8009976
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 ml of saline solution daily) for ten days
Study: 2782336
Drug: Group III:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group III: Clindamycin and tobramycin for >= 48 hours followed by 7-day course of oral Augmentin
Study: 29300197
Drug: Sucrose solution
Normalized name: TootSweet 24% Oral Sucrose Solution
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucrose solution (25%; 0.5 mL/kg) administered 2 minutes before procedures
Study: 22622278
Drug: EMDR treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMDR treatment with one-week sessions
Study: 22622278
Drug: Sertraline (SSRI)
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sertraline (SSRI) treatment
Study: 20195553
Drug: Patient-controlled oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled oral analgesia (PCOA)
Study: 20195553
Drug: RN-administered short-acting
Normalized name: Short-acting sulfonamides
Approvals — FDA: no, EMA: no, PMDA: no
Description: RN-administered short-acting oral opioids
Study: 20195553
Drug: RN administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RN administration
Study: 15956047
Drug: Iron medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron medicine (ferrous gluconate at 3 mg/kg of elemental iron once daily)
Study: 15956047
Drug: Iron fortified
Normalized name: INFANT FORMULA SMA IRON FORTIFIED PWD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron fortified follow-on milk (12 mg/l ferrous iron)
Study: 15956047
Drug: Iron fortified
Normalized name: INFANT FORMULA SMA IRON FORTIFIED PWD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron fortified partially modified cows' milk (12.9 mg/l ferrous iron)
Study: 12095498
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of clomiphene citrate (CC) on days 1-5
Study: 1922235
Drug: Cefixime 400
Normalized name: cefixime 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefixime 400 mg (oral)
Study: 1922235
Drug: Cefixime 800
Normalized name: Cefixime
DrugBank: Cefixime (DB00671)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefixime 800 mg (oral)
Study: 1922235
Drug: Ceftriaxone 250
Normalized name: ceftriaxone 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 250 mg (intramuscular)
Study: 6981167
Drug: Trimethoprim-sulfamethoxazole (TMP-SMZ)
Normalized name: sulfamethoxazole / trimethoprim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-sulfamethoxazole (TMP-SMZ) - 160 mg of TMP plus 800 mg of SMZ, two double-strength tablets twice daily for two days
Study: 6981167
Drug: Ampicillin plus
Normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ampicillin plus probenecid - 3.5 g of ampicillin plus 1 g of probenecid, single dose
Study: 30819688
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide (TA) 4 mg
Study: 29402270
Drug: Sitagliptin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin treatment group
Study: 27621258
Drug: Self-help cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-help cognitive behaviour therapy (CBT) intervention lasting 4 weeks
Study: 27621258
Drug: No treatment-wait
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment-wait control condition (NTWC)
Study: 20197013
Drug: Saquinavir/ritonavir 1,000/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saquinavir/ritonavir 1,000/100 mg twice daily for 2 weeks
Study: 20197013
Drug: Control (baseline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (baseline digoxin dose of 0.5 mg)
Study: 17437688
Drug: Selective serotonin
Normalized name: Selective serotonin (5HT1) agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective serotonin reuptake inhibitors (SSRIs); specific dosage and duration not available
Study: 15560958
Drug: 100 mg/day
Normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/day clozapine
Study: 15560958
Drug: 300 mg/day
Normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg/day clozapine
Study: 15560958
Drug: 600 mg/day
Normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg/day clozapine
Study: 15560958
Drug: 100 mg/day
Normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/day clozapine (heavy smokers)
Study: 12930926
Drug: Granulocyte colony-stimulating
Normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte colony-stimulating factor (G-CSF) given concurrently with chemotherapy
Study: 12930926
Drug: Granulocyte colony-stimulating
Normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte colony-stimulating factor (G-CSF) in standard-risk AML
Study: 12930926
Drug: No G-CSF
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No G-CSF in standard-risk AML
Study: 12930926
Drug: Granulocyte colony-stimulating
Normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte colony-stimulating factor (G-CSF) in unfavorable prognosis subgroup
Study: 10519559
Drug: Flexion‐distraction technique
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flexion‐distraction technique (active treatment)
Study: 10519559
Drug: Sham adjustments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham adjustments (placebo treatment)
Study: 2391397
Drug: Acetaminophen sustained
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen sustained release (SR) high dose (2000 mg)
Study: 2391397
Drug: Acetaminophen immediate
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen immediate plus sustained release (IR + SR) high dose (500 + 1500 mg)
Study: 2391397
Drug: Acetaminophen standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen standard tablet high dose (1000 mg)
Study: 2391397
Drug: Acetaminophen standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen standard tablet low dose (500 mg)
Study: 2391397
Drug: Acetaminophen sustained
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen sustained release (SR) low dose (1000 mg)
Study: 2391397
Drug: Acetaminophen immediate
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen immediate plus sustained release (IR + SR) low dose (250 + 750 mg)
Study: 24552803
Drug: Personal oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personal oxygen supplement (OS)
Study: 17913322
Drug: Lithium administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium administration for two weeks
Study: 21960699
Drug: Nebulized albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized albuterol 2.5 mg
Study: 16002915
Drug: Nebulized albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized albuterol 5 mg
Study: 1710624
Drug: 24 IU
Normalized name: Nasopro 24
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 24 IU GH administered intramuscularly on alternate days starting on cycle day 4
Study: 1710624
Drug: Placebo (sterile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (sterile saline) administered intramuscularly on alternate days starting on cycle day 4
Study: 1710624
Drug: 24 IU
Normalized name: Nasopro 24
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 24 IU GH administered intramuscularly
Study: 6798616
Drug: Alprazolam (0.25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (0.25, 0.5, and 1.0 mg)
Study: 6798616
Drug: Diazepam (2,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (2, 5, and 10 mg)
Study: 31994365
Drug: Oxycodone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone (10 mg)/Naloxone (5 mg) for the first 48 hours
Study: 31994365
Drug: Morphine (0.2-0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (0.2-0.4 mg/kg/day)
Study: 25373836
Drug: Patient requests
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient requests for pain medications
Study: 19320662
Drug: Vildagliptin plus
Normalized name: vildagliptin
DrugBank: Vildagliptin (DB04876)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Vildagliptin plus high-dose metformin combination therapy (50 mg + 1000 mg twice daily)
Study: 19320662
Drug: Vildagliptin plus
Normalized name: vildagliptin
DrugBank: Vildagliptin (DB04876)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Vildagliptin plus low-dose metformin combination therapy (50 mg + 500 mg twice daily)